At present, anti-CTLA-4 drugs for the treatment of NSCLC are ipilimumab and tremelimumab; however, there are clear differences with regard to the toxicity of these two drugs in different organs. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.